Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19

Simple item page
dc.contributor.authorFelipe Reyes, Luis
dc.contributor.authorRodriguez, Alejandro
dc.contributor.authorBastidas, Alirio
dc.contributor.authorParra-Tanoux, Daniela
dc.contributor.authorFuentes, Yuli, V
dc.contributor.authorGarcia-Gallo, Esteban
dc.contributor.authorMoreno, Gerard
dc.contributor.authorOspina-Tascon, Gustavo
dc.contributor.authorHernandez, Gleen
dc.contributor.authorSilva, Edwin
dc.contributor.authorDiaz, Ana Maria
dc.contributor.authorJibaja, Manuel
dc.contributor.authorVera-Alarcon, Magdalena
dc.contributor.authorDiaz, Emilio
dc.contributor.authorBodi, Maria
dc.contributor.authorSole-Violan, Jordi
dc.contributor.authorFerrer, Ricard
dc.contributor.authorAlbaya-Moreno, Antonio
dc.contributor.authorSocias, Lorenzo
dc.contributor.authorEstella, Angel
dc.contributor.authorLoza-Vazquez, Ana
dc.contributor.authorJorge-Garcia, Ruth
dc.contributor.authorSancho, Isabel
dc.contributor.authorMartin-Loeches, Ignacio
dc.date.accessioned2024-01-10T12:37:11Z
dc.date.available2024-01-10T12:37:11Z
dc.date.issued2022
dc.description.abstractPurpose: Dexamethasone is the only drug that has consistently reduced mortality in patients with COVID-19, es-pecially in patients needing oxygen or invasive mechanical ventilation. However, there is a growing concern about the relation of dexamethasone with the unprecedented rates of ICU-acquired respiratory tract infections (ICU-RTI) observed in patients with severe COVID-19. Methods: This was a multicenter, prospective cohort study; conducted in ten countries in Latin America and Europe. We included patients older than 18 with confirmed SARS-CoV-2 requiring ICU admission. A multivariate logistic regression and propensity score matching (PSM) analysis was conducted to determine the relation be-tween dexamethasone treatment and ICU-RTI. Results: A total of 3777 patients were included. 2065 (54.7%) were treated with dexamethasone within the first 24 h of admission. After performing the PSM, patients treated with dexamethasone showed significantly higher proportions of VAP (282/1652 [17.1%] Vs. 218/1652 [13.2%], p = 0.014). Also, dexamethasone treatment was identified as an adjusted risk factor of ICU-RTI in the multivariate logistic regression model (OR 1.64; 95%CI: 1.37-1.97; p < 0.001).
dc.fechaingreso.objetodigital27-03-2024
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.jcrc.2022.154014
dc.identifier.eissn1557-8615
dc.identifier.issn0883-9441
dc.identifier.urihttps://doi.org/10.1016/j.jcrc.2022.154014
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/76780
dc.identifier.wosidWOS:000766785400008
dc.information.autorucFacultad de Medicina; Vera Alarcon, Maria Magdalena; S/I; 226652
dc.language.isoen
dc.nota.accesocontenido completo
dc.publisherW B SAUNDERS CO-ELSEVIER INC
dc.rightsacceso abierto
dc.subjectDexamethasone
dc.subjectCOVID-19
dc.subjectCritical care
dc.subjectSevere COVID-19
dc.subjectPneumonia
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleDexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19
dc.typeartículo
dc.volumen69
sipa.codpersvinculados226652
sipa.indexWOS
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-03-27. Dexamethasone as risk-factor for ICU-acquired respiratory tract.pdf
Size:
736.57 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas